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The primary structure of a murine senile amyloid protein (AS sAM) was determined. The protein consists 
of a single polypeptide chain of 78 amino acid residues. The amino-terminus is blocked with pyrrolidone- 
carboxylic acid. The sequence differs from that of the known murine amyloid A protein and is highly homo- 
logous to human apolipoprotein (apo) A-II. The result indicates that the putative precursor of the senile 
amyloid protein is apo A-II in mice. 
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1. INTRODUCTION 
Amyloidosis is characterized by extracellular 
deposition of fibrillar amyloid protein. In human, 
the systemic amyloidoses have been classified as 
immunoglobulin (primary), reactive (secondary) 
and heredofamilial [l]. They have been well 
-characterized biochemically but their pathogenesis 
is not clearly understood. 
The mouse has been considered an appropriate 
animal for studying a wide variety of pathological 
processes. Therefore the murine model has been 
used to elucidate amyloidogenesis. In mice, sec- 
ondary amyloidosis has been produced experimen- 
tally by parenteral administration of a variety of 
inflammatory agents. It has been shown that 
murine amyloid A protein (AA) is highly homo- 
logous to human AA and is derived from one 
isotype of serum AA protein (SAA), which is apo 
Abbreviations: CNBr, cyanogen bromide; SAM, 
senescence accelerated mouse; HDL, high density 
lipoprotein; HPLC, high-performance liquid chroma- 
tography; PTH, phenylthiohydantoin 
SAA2 protein [2]. On the other hand, though spon- 
taneous amyloidosis has been reported to occur in 
various strains of mice, this type of amyloidosis is 
not well characterized biochemically. 
A murine model of accelerated senescence, con- 
sisting of SAM-P (accelerated senescence prone 
mice, P/l, P/2, P/3 and P/4 series) and SAM-R 
(accelerated senescence resistance mice, R/ 1, R/2 
and R/3 series), which have normal ageing 
characteristics, was developed in our laboratory 
[3]. In these senescence accelerated mice, spon- 
taneous age-associated amyloidosis is one of the 
most characteristic pathological findings [4]. A 
unique amyloid fibril protein termed ‘ASSAM’ has 
been isolated from SAM-P/l. This protein has 
been shown to differ from the amyloid proteins 
from any other spontaneous or secondary murine 
amyloidosis in their biochemical and im- 
munochemical properties [5,6]. 
Here we report the primary structure of ASSAM 
and find high homology between ASSAM and 
human apo A-II. 
Published by Elsevier Science Publrshers B. V. (Biomedical Division) 
00145793/86/$3.50 0 1986 Federation of European Biochemical Societies 149 
Volume 203, number 2 FEBS LETTERS July 1986 
2. MATERIALS AND METHODS 
2.1. Purification of ASSAM- 1 and ASSAM-~ 
ASsAM was isolated from the water soluble frac- 
tion from the livers of SAM-P/l mice and purified 
by gel chromatography through Sephadex G-100 
as described [5]. Analysis of this material on 
DEAE-cellulose (DE52) chromatography with a 
linear gradient elution from 0.01 to 0.1 M Tris- 
HCl, pH 8.2, in 6 M urea gave two peaks, 
designated ASSAM - 1 (major component) and 
ASSAM-2 (minor component). The proteins in 
each peak were further purified by reverse-phase 
HPLC on a Baker bond wide pore Butyl column 
(0.46 x 25 cm, C4, 330 A). The column was 
equilibrated with 0.1 Vo trifluoroacetic acid (TFA) 
and elution was performed by a linear gradient 
(O-60%) of 2-propanol/acetonitrile (7 : 3, v/v) in 
0.1% TFA for 1 h at a flow rate of 1 ml/min. 
2.2. Removal and identification of amino- 
terminal pyrrolidone-carboxylic acid (PCA) 
Removal of the amino-terminal PCA from the 
protein was performed using calf liver 
pyroglutamyl peptidase (L-pyroglutamyl-peptide 
hydrolase, EC 3.4.19.3, Sigma) by the method of 
Podell and Abraham [7]. The PCA released was 
identified by reverse-phase HPLC according to the 
method described (81. Authentic PCA, AC-Glu and 
Ac-Gln were used for comparison. 
2.3. Peptide fragmentation and separation on 
reverse-phase HPLC 
ASSAM - 1 and ASSAM- 2 were separately 
digested with Achromobacter lyticus protease I 
(AP) at 37°C for 6 h in 10 mM Tris, pH 9.5 (en- 
zyme/substrate = 1: 100, mol/mol). Methionyl 
bonds in ASSAM - 1, - 2 were cleaved with a 
lOO-fold molar excess of CNBr to methionine 
residues in 70% formic acid at 37°C for 18 h. 
Digestion of A!&M - 1, - 2 with Staphylococcus 
aureus V8 protease (SP) was performed in 1.5% 
NH4HC03 at 37°C for 18 h (enzyme/substrate = 
1: 100, mol/mol). Peptides were fractionated on a 
reverse-phase C-4 column as described above. 
2.4. Amino acid and sequence analyses 
Amino acid analysis was carried out with a 
Hitachi 8358 amino acid analyzer. Proteins were 
hydrolyzed for 24 or 72 h in 6 N HCl containing 
150 
0.2% phenol at 110°C in vacua. Peptides were 
hydrolyzed by the same method for 24 h. 
Automated Edman degradation was performed 
with a 470A protein sequencer (Applied 
Biosystem) using the standard program for se- 
quencing [9]. PTH-amino acids were identified by 
reverse-phase HPLC as reported [lo]. 
3. RESULTS AND DISCUSSION 
ASSAM - 1 and ASSAM - 2 each exhibited a single 
band on polyacrylamide gel electrophoresis con- 
taining 8 ‘M urea, and ASSAM - 2 has a slightly 
greater mobility than ASSAM- 1 (not shown). 
Table 1 shows the amino acid composition of 
ASSAM - 1 and ASSAM - 2. Both proteins gave the 
same amino acid compositions and are rich in 
glutamic acidjglutamine and lack half-cystine and 
tryptophan. The values are compatible, within ex- 
Table 1 
Amino acid composition of ASSAM - 1 and ASSAM - 2 
Amino acid 
Asp 
Thrb 
Serb 
Ghl 
Pro 
GJY 
Ala 
%Cys 
Val’ 
Met 
Be’ 
Leu 
Tyr 
Phe 
Lys 
His 
Trp 
Arg 
Residues/m01 
ASSAM - 1 ASSAM - 2 
5.0(5)= 5.2(5) 
5.9(6) 5.8(6) 
7.6(8) 7.6(8) 
15.3(15) 15.2(15) 
2.8(3) 2.5(3) 
3.4(3) 3.2(3) 
8.0(8) 8.4(8) 
0 (0) 0 (0) 
2.9(3) 3.3(3) 
2.5(3) 2.6(3) 
1.0(l) 1.2(L) 
6.9(7) 7.4(7) 
2.9(3) 2.9(3) 
4.9(5) 4.7(5) 
5.9(6) 5.5(6) 
1.1(l) 1.0(l) 
0 (0) 0 (0) 
1.2(l) 1.4(l) 
Total (78) (78) 
a Numbers in parentheses are based on the amino acid 
sequence (fig. 1) 
b Values are those extrapolated to zero hour 
’ Values are those of 72 h hydrolysis 
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perimental error, with those calculated from the 
established amino acid sequence as shown later. 
When Edman degradation was performed on the 
intact A&AM - 1, no PTH-amino acids were found 
and a blocked amino-terminus was suspected. The 
protein was then incubated with calf liver 
pyroglutamyl peptidase. As a result, the amino 
group of the second residue (Ala) from the N- 
terminus was exposed and the pyroglutamic acid 
released was identified by reverse-phase HPLC [8]. 
By subsequent automated Edman degradation 
with a gas-phase sequencer, the sequence of the 
first 27 amino-terminal residues of the protein 
from Ala’ was determined. 
To determine the complete amino acid sequence 
of ASSAM - 1, the protein was individually sub- 
jected to digestion with AP, SP, and chemical 
cleavage with CNBr. Nine peptides (APl-AP8 
and AP6-7) were isolated by digestion with AP the 
yield being 25-88%. Except for a peptide blocked 
at the amino-terminus (API), six peptides 
(AP2-AP6 and AP8) were completely and two 
(AP6-7 and AP7) partially sequenced. In this case, 
AP cleaved all lysyl bonds in the protein and par- 
tially the Arg54-Ser” bond (about 50%). To align 
the sequenced AP peptides and elucidate the am- 
biguous sequences in AP6-7 and AP7, ASSAM - 1 
was fragmented with SP and by CNBr. Seven pep- 
tides (SPl-SP7) were obtained by the V8 protease 
digestion and four (CBl-CB4) by CNBr cleavage. 
The amino acid sequences of seven critical peptides 
(SP2-SPS, SP7, CB2 and CB4) were determined 
and the complete amino acid sequence of 
ASSAM - 1 was thus established as shown in fig. 1. 
The protein consists of a single polypeptide chain 
of 78 amino acid residues with an M, of 8721. The 
amino acid sequence of ASSAM - 1 differs from 
those of the known amyloid proteins [2,11-141. 
Though heterogeneity of the amino-terminus has 
been often reported in the amyloid protein, 
ASSAM - 1 sequenced in the present experiment 
gave PCA as a sole N-terminus. The amino acid se- 
quence of ASSAM - 2 was also determined by the 
same procedure (not shown). It is surprising that, 
in spite of the different electrophoretic mobility of 
ASSAM - 1 and ASSAM -2, their amino acid se- 
quences are identical. While we have no definite 
explanation for this reason, it seems likely that 
native A&AM-~ may undergo some minor but 
distinct modification of the tertiary structure, its 
1 IO 20 
~AOGQOMQSLFTOYF~SNTEYGKOL”EKA3~ 
l 
I API 1 ~APZ-WA4l 
I SPI I-sPZ---wtSP3- 
+cm--+ +CB2----tl~CC3- 
LO 50 60 
TSEIQSOAKAVFEKTHEQLTPLVRSAGTSL 
C--API- bAP5-W I----AP6 -I---AP7- 
-AP6-7 
-sP% -SPC-I-SK_* -SP6----- 
CB3 
70 
VNFFSSLMNLEEKPAPAA 
-----AP7- k-AP0-m 
-AP6-7--t----1 
-SP6--SP7- 
-CB3----I -c01- 
Fig.1. Amino acid sequence of ASSAM - 1. Residues 
identified by Edman degradation are shown by arrows. 
The solid line denotes the portions of the peptides whose 
amino acid compositions were determined but sequences 
were not analyzed. AP, SP and CB represent peptides 
obtained Achromobacter lyticus protease I, 
Staphylococcus aureus Vg protease digestion and 
cyanogen bromide degradation, respectively. 
electrophoretic behavior being affected in the 
absence of SDS. 
It should be noted that high homology is present 
between the primary structures of ASSAM- 1 or 
ASSAM -2 and human apo A-II (fig.2). The two 
structures are identical in 43 of 78 residues (55%). 
It has been shown that apo A-II is a major con- 
stituent of HDL and that a putative precursor of 
ASSAM, termed apo SASSAM (serum X&AM-related 
antigenic substance), is associated with circulating 
HDL [la]. The results obtained in this study sug- 
gest that apo SASSAM is the murine apo A-II. 
Although the metabolism and the biosynthesis of 
human apo A-II were examined [17,18], little is 
known about its function. Therefore we believe 
that the elucidation of this amyloidogenesis should 
aid in determining the function of human apo A- 
II. 
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ASSAM-1 
Human 3po A-II 
Fig.2. Comparison of the amino acid sequence between ASSAM - 1 and human apo A-11(15). Identical residues are 
boxed. 
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